Eris Lifesciences Limited

NSEI:ERIS Stock Report

Market Cap: ₹186.0b

Eris Lifesciences Valuation

Is ERIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ERIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ERIS (₹1366.9) is trading above our estimate of fair value (₹1106.74)

Significantly Below Fair Value: ERIS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ERIS?

Key metric: As ERIS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ERIS. This is calculated by dividing ERIS's market cap by their current earnings.
What is ERIS's PE Ratio?
PE Ratio53.4x
Earnings₹3.48b
Market Cap₹186.04b

Price to Earnings Ratio vs Peers

How does ERIS's PE Ratio compare to its peers?

The above table shows the PE ratio for ERIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average42.4x
524558 Neuland Laboratories
67.9x33.9%₹189.8b
MARKSANS Marksans Pharma
40.4x22.3%₹140.1b
524742 Caplin Point Laboratories
29.9x13.6%₹147.7b
APLLTD Alembic Pharmaceuticals
31.5x21.5%₹204.0b
ERIS Eris Lifesciences
53.4x30.7%₹186.0b

Price-To-Earnings vs Peers: ERIS is expensive based on its Price-To-Earnings Ratio (53.4x) compared to the peer average (42.4x).

Price to Earnings Ratio vs Industry

How does ERIS's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
ERIS 53.4xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ERIS is expensive based on its Price-To-Earnings Ratio (53.4x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is ERIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ERIS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.4x
Fair PE Ratio47.7x

Price-To-Earnings vs Fair Ratio: ERIS is expensive based on its Price-To-Earnings Ratio (53.4x) compared to the estimated Fair Price-To-Earnings Ratio (47.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ERIS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,366.90
₹1,503.11
+10.0%
9.0%₹1,680.00₹1,230.00n/a9
Nov ’25₹1,347.15
₹1,503.11
+11.6%
9.0%₹1,680.00₹1,230.00n/a9
Oct ’25₹1,324.25
₹1,334.44
+0.8%
14.8%₹1,680.00₹1,075.00n/a9
Sep ’25₹1,388.20
₹1,243.33
-10.4%
11.0%₹1,580.00₹1,075.00n/a9
Aug ’25₹1,119.35
₹1,110.56
-0.8%
7.6%₹1,270.00₹980.00n/a9
Jul ’25₹1,050.15
₹1,091.67
+4.0%
8.2%₹1,270.00₹950.00n/a9
Jun ’25₹916.10
₹1,091.67
+19.2%
8.2%₹1,270.00₹950.00n/a9
May ’25₹895.95
₹1,079.44
+20.5%
9.0%₹1,230.00₹930.00n/a9
Apr ’25₹850.05
₹1,079.44
+27.0%
9.0%₹1,230.00₹930.00n/a9
Mar ’25₹886.05
₹1,075.63
+21.4%
8.4%₹1,230.00₹950.00n/a8
Feb ’25₹906.65
₹1,032.78
+13.9%
10.2%₹1,230.00₹900.00n/a9
Jan ’25₹905.80
₹1,013.33
+11.9%
8.9%₹1,170.00₹890.00n/a9
Dec ’24₹926.25
₹993.89
+7.3%
7.1%₹1,110.00₹890.00n/a9
Nov ’24₹864.45
₹970.00
+12.2%
6.7%₹1,110.00₹890.00₹1,347.159
Oct ’24₹876.30
₹916.50
+4.6%
7.7%₹1,040.00₹790.00₹1,324.2510
Sep ’24₹812.35
₹902.78
+11.1%
6.7%₹995.00₹790.00₹1,388.209
Aug ’24₹795.90
₹799.44
+0.4%
6.4%₹920.00₹735.00₹1,119.359
Jul ’24₹698.90
₹785.00
+12.3%
7.5%₹920.00₹720.00₹1,050.159
Jun ’24₹640.55
₹785.00
+22.6%
7.5%₹920.00₹720.00₹916.109
May ’24₹631.25
₹791.11
+25.3%
10.7%₹1,000.00₹690.00₹895.959
Apr ’24₹572.10
₹805.56
+40.8%
9.6%₹1,000.00₹710.00₹850.059
Mar ’24₹630.90
₹827.22
+31.1%
6.9%₹975.00₹770.00₹886.059
Feb ’24₹612.85
₹827.22
+35.0%
6.9%₹975.00₹770.00₹906.659
Jan ’24₹647.25
₹869.44
+34.3%
6.7%₹975.00₹800.00₹905.809
Dec ’23₹669.95
₹869.44
+29.8%
6.7%₹975.00₹800.00₹926.259
Nov ’23₹728.90
₹875.50
+20.1%
6.6%₹975.00₹800.00₹864.4510

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

7D

-0.4%

1Y

58.1%